S&P 500   3,617.53 (-0.57%)
DOW   29,582.35 (-1.10%)
QQQ   299.16 (+0.05%)
AAPL   120.46 (+3.32%)
MSFT   212.81 (-1.12%)
FB   275.27 (-0.91%)
GOOGL   1,754.81 (-1.80%)
AMZN   3,161.17 (-1.07%)
TSLA   578.64 (-1.22%)
NVDA   531.75 (+0.25%)
BABA   264.09 (-4.48%)
CGC   28.88 (-0.41%)
GE   10.25 (-1.44%)
MU   64.21 (-0.03%)
AMD   92.10 (+5.63%)
T   28.75 (-0.96%)
NIO   51.43 (-4.76%)
F   9.11 (+0.22%)
ACB   11.69 (+11.65%)
NFLX   488.78 (-0.53%)
BA   211.71 (-2.21%)
GILD   59.99 (-0.07%)
DIS   147.30 (+0.12%)
S&P 500   3,617.53 (-0.57%)
DOW   29,582.35 (-1.10%)
QQQ   299.16 (+0.05%)
AAPL   120.46 (+3.32%)
MSFT   212.81 (-1.12%)
FB   275.27 (-0.91%)
GOOGL   1,754.81 (-1.80%)
AMZN   3,161.17 (-1.07%)
TSLA   578.64 (-1.22%)
NVDA   531.75 (+0.25%)
BABA   264.09 (-4.48%)
CGC   28.88 (-0.41%)
GE   10.25 (-1.44%)
MU   64.21 (-0.03%)
AMD   92.10 (+5.63%)
T   28.75 (-0.96%)
NIO   51.43 (-4.76%)
F   9.11 (+0.22%)
ACB   11.69 (+11.65%)
NFLX   488.78 (-0.53%)
BA   211.71 (-2.21%)
GILD   59.99 (-0.07%)
DIS   147.30 (+0.12%)
S&P 500   3,617.53 (-0.57%)
DOW   29,582.35 (-1.10%)
QQQ   299.16 (+0.05%)
AAPL   120.46 (+3.32%)
MSFT   212.81 (-1.12%)
FB   275.27 (-0.91%)
GOOGL   1,754.81 (-1.80%)
AMZN   3,161.17 (-1.07%)
TSLA   578.64 (-1.22%)
NVDA   531.75 (+0.25%)
BABA   264.09 (-4.48%)
CGC   28.88 (-0.41%)
GE   10.25 (-1.44%)
MU   64.21 (-0.03%)
AMD   92.10 (+5.63%)
T   28.75 (-0.96%)
NIO   51.43 (-4.76%)
F   9.11 (+0.22%)
ACB   11.69 (+11.65%)
NFLX   488.78 (-0.53%)
BA   211.71 (-2.21%)
GILD   59.99 (-0.07%)
DIS   147.30 (+0.12%)
S&P 500   3,617.53 (-0.57%)
DOW   29,582.35 (-1.10%)
QQQ   299.16 (+0.05%)
AAPL   120.46 (+3.32%)
MSFT   212.81 (-1.12%)
FB   275.27 (-0.91%)
GOOGL   1,754.81 (-1.80%)
AMZN   3,161.17 (-1.07%)
TSLA   578.64 (-1.22%)
NVDA   531.75 (+0.25%)
BABA   264.09 (-4.48%)
CGC   28.88 (-0.41%)
GE   10.25 (-1.44%)
MU   64.21 (-0.03%)
AMD   92.10 (+5.63%)
T   28.75 (-0.96%)
NIO   51.43 (-4.76%)
F   9.11 (+0.22%)
ACB   11.69 (+11.65%)
NFLX   488.78 (-0.53%)
BA   211.71 (-2.21%)
GILD   59.99 (-0.07%)
DIS   147.30 (+0.12%)
Log in
NASDAQ:AERI

Aerie Pharmaceuticals Stock Forecast, Price & News

$12.55
-0.45 (-3.46 %)
(As of 11/30/2020 03:27 PM ET)
Add
Compare
Today's Range
$12.45
Now: $12.55
$13.09
50-Day Range
$9.12
MA: $11.43
$13.05
52-Week Range
$9.01
Now: $12.55
$26.26
Volume9,127 shs
Average Volume855,326 shs
Market Capitalization$587.53 million
P/E RatioN/A
Dividend YieldN/A
Beta0.7
Aerie Pharmaceuticals, Inc., an ophthalmic pharmaceutical company, focuses on the discovery, development, and commercialization of first-in-class therapies for the treatment of glaucoma, dry eye, retinal diseases, and other eye diseases. Its products include Rhopressa, a once-daily eye drop to reduce elevated intraocular pressure (IOP) in patients with glaucoma or ocular hypertension; and Rocklatan, a once-daily fixed-dose combination of Rhopressa and latanopros to reduce IOP to treat patients with open-angle glaucoma and ocular hypertension. The company is also developing AVX-012, a clinical-stage dry eye product candidate; and AR-1105 and AR-13503 sustained-release implants for treating retinal diseases. Aerie Pharmaceuticals, Inc. has a collaborative research, development, and licensing agreement with DSM. Aerie Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Durham, North Carolina.
Read More
Aerie Pharmaceuticals logo

Beat the Market (BTM) Rank

Analyst Opinion: 4.3Community Rank: 2.9Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.91 out of 5 stars


Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:AERI
CUSIPN/A
Phone919-237-5300
Employees380

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$69.89 million
Book Value$1.28 per share

Profitability

Net Income$-199,580,000.00
Net Margins-231.05%

Miscellaneous

Market Cap$587.53 million
Next Earnings Date2/18/2021 (Estimated)
OptionableOptionable
$12.55
-0.45 (-3.46 %)
(As of 11/30/2020 03:27 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive AERI News and Ratings via Email

Sign-up to receive the latest news and ratings for AERI and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Aerie Pharmaceuticals (NASDAQ:AERI) Frequently Asked Questions

How has Aerie Pharmaceuticals' stock been impacted by Coronavirus?

Aerie Pharmaceuticals' stock was trading at $14.55 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, AERI shares have decreased by 14.0% and is now trading at $12.52.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Aerie Pharmaceuticals?

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aerie Pharmaceuticals in the last year. There are currently 1 sell rating, 2 hold ratings and 9 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Aerie Pharmaceuticals
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Aerie Pharmaceuticals?

Wall Street analysts have given Aerie Pharmaceuticals a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Aerie Pharmaceuticals wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Aerie Pharmaceuticals' next earnings date?

Aerie Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, February 18th 2021.
View our earnings forecast for Aerie Pharmaceuticals
.

How were Aerie Pharmaceuticals' earnings last quarter?

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) announced its quarterly earnings data on Tuesday, November, 10th. The company reported ($0.65) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.81) by $0.16. Aerie Pharmaceuticals had a negative net margin of 231.05% and a negative return on equity of 135.57%.
View Aerie Pharmaceuticals' earnings history
.

What price target have analysts set for AERI?

12 analysts have issued twelve-month target prices for Aerie Pharmaceuticals' shares. Their forecasts range from $9.00 to $40.00. On average, they expect Aerie Pharmaceuticals' stock price to reach $26.45 in the next twelve months. This suggests a possible upside of 111.3% from the stock's current price.
View analysts' price targets for Aerie Pharmaceuticals
.

Are investors shorting Aerie Pharmaceuticals?

Aerie Pharmaceuticals saw a decrease in short interest in October. As of October 30th, there was short interest totaling 6,440,000 shares, a decrease of 17.0% from the October 15th total of 7,760,000 shares. Based on an average daily volume of 738,700 shares, the short-interest ratio is currently 8.7 days. Currently, 14.3% of the company's shares are short sold.
View Aerie Pharmaceuticals' Short Interest
.

Who are some of Aerie Pharmaceuticals' key competitors?

What other stocks do shareholders of Aerie Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Aerie Pharmaceuticals investors own include Canopy Growth (CGC), Nicox (NICXF), Micron Technology (MU), Melinta Therapeutics (MLNT), BioMarin Pharmaceutical (BMRN), Gilead Sciences (GILD), Puma Biotechnology (PBYI), NVIDIA (NVDA), Wells Fargo & Company (WFC) and Alibaba Group (BABA).

Who are Aerie Pharmaceuticals' key executives?

Aerie Pharmaceuticals' management team includes the following people:
  • Dr. Vicente J. Anido Jr., CEO & Chairman (Age 67, Pay $1.13M)
  • Mr. Thomas A. Mitro, Pres & COO (Age 62, Pay $582.78k)
  • Dr. Casey C. Kopczynski, Co-Founder & Chief Scientific Officer (Age 59, Pay $582.51k)
  • Mr. Richard James Rubino CPA, CFO, Sec. & Treasurer (Age 62, Pay $620.37k)
  • Mr. John W. LaRocca Esq., Gen. Counsel & Assistant Sec. (Age 54, Pay $576.3k)
  • Mr. Jeffrey Calabrese, Director of Accounting
  • Ms. Ami Bavishi, Director of Investor Relations
  • Ms. Charlene E Davis, VP & Chief Compliance Officer
  • Mr. Tad Heitmann, Head of Communications
  • Ms. Deanne F. Melloy, VP of Marketing (Age 52)

What is Aerie Pharmaceuticals' stock symbol?

Aerie Pharmaceuticals trades on the NASDAQ under the ticker symbol "AERI."

Who are Aerie Pharmaceuticals' major shareholders?

Aerie Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional investors include C WorldWide Group Holding A S (3.13%), William Blair Investment Management LLC (3.05%), Levin Capital Strategies L.P. (2.88%), State Street Corp (2.16%), Rhenman & Partners Asset Management AB (1.83%) and Pinnacle Associates Ltd. (1.13%). Company insiders that own Aerie Pharmaceuticals stock include Casey C Kopczynski, Foresite Capital Fund Ii, LP, Foresite Capital Management Ii, Gerald D Cagle, Richard J Rubino and Vicente Anido Jr.
View institutional ownership trends for Aerie Pharmaceuticals
.

Which major investors are selling Aerie Pharmaceuticals stock?

AERI stock was sold by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Levin Capital Strategies L.P., Tarsadia Capital LLC, State Street Corp, Sei Investments Co., Cubist Systematic Strategies LLC, CWM LLC, and Pinnacle Associates Ltd.. Company insiders that have sold Aerie Pharmaceuticals company stock in the last year include Casey C Kopczynski, and Gerald D Cagle.
View insider buying and selling activity for Aerie Pharmaceuticals
.

Which major investors are buying Aerie Pharmaceuticals stock?

AERI stock was bought by a variety of institutional investors in the last quarter, including C WorldWide Group Holding A S, Rhenman & Partners Asset Management AB, Granite Investment Partners LLC, Voloridge Investment Management LLC, Worth Venture Partners LLC, Aperio Group LLC, William Blair Investment Management LLC, and Envestnet Asset Management Inc.. Company insiders that have bought Aerie Pharmaceuticals stock in the last two years include Foresite Capital Fund Ii, LP, Foresite Capital Management Ii, Richard J Rubino, and Vicente Anido Jr.
View insider buying and selling activity for Aerie Pharmaceuticals
.

How do I buy shares of Aerie Pharmaceuticals?

Shares of AERI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Aerie Pharmaceuticals' stock price today?

One share of AERI stock can currently be purchased for approximately $12.52.

How big of a company is Aerie Pharmaceuticals?

Aerie Pharmaceuticals has a market capitalization of $586.12 million and generates $69.89 million in revenue each year. The company earns $-199,580,000.00 in net income (profit) each year or ($3.40) on an earnings per share basis. Aerie Pharmaceuticals employs 380 workers across the globe.

What is Aerie Pharmaceuticals' official website?

The official website for Aerie Pharmaceuticals is www.aeriepharma.com.

How can I contact Aerie Pharmaceuticals?

Aerie Pharmaceuticals' mailing address is 4301 Emperor Boulevard Suite 400, North Carolina NC, 27703. The company can be reached via phone at 919-237-5300 or via email at [email protected]

This page was last updated on 11/30/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.